Ten stocks stood their ground on Thursday, boasting double-digit gains amid a pessimistic broader market, thanks to strong earnings performance and a series of merger news that boosted buying appetite. Of the 10 firms, nine notably touched new all-time highs.
Meanwhile, Wall Street’s major indices all finished in the red, led by the Nasdaq, which fell 1.57 percent, followed by the S&P 500, which declined 0.99 percent, and the Dow Jones, which dropped 0.23 percent.
In this article, we spotlight the 10 companies that led the charge on Thursday and explore the reasons behind their gains.
To compile the list, we focused on stocks with a market capitalization of more than $2 billion and a trading volume of 5 million shares.
Photo by Tima Miroshnichenko on Pexels
10. Immunovant Inc. (NASDAQ:IMVT)
Immunovant grew by 14.64 percent on Thursday to close at $24.82 apiece as investors gobbled up its shares ahead of the results of its third quarter earnings performance in the next few days.
According to Immunovant Inc. (NASDAQ:IMVT), it is set to announce the results of its financial and operating highlights before market open on November 10, 2025. A conference call will be held to elaborate on the results.
In the second quarter of the year, the company widened its net loss by 38 percent to $120.6 million from $87.15 million in the same period last year, as total operating expenses grew by 35 percent to $127 million from $94 million year-on-year.
In other developments, traders also may have positioned their portfolios following unconfirmed buzz that Immunovant Inc. (NASDAQ:IMVT) is set to be acquired by one of its largest shareholders, Roivant Sciences Ltd.
9. Indivior PLC (NASDAQ:INDV)
Indivior climbed for a third straight day on Thursday to reach a new all-time high, as investors cheered a stellar earnings performance and a highly optimistic business outlook for the rest of the year.
At intra-day trade, the stock soared to its highest 52-week price of $30.55 before paring gains to end the day just up by 15.41 percent at $29.13 apiece.
In an updated report, Indivior PLC (NASDAQ:INDV) said it grew its net income by 91 percent to $42 million from $20 million in the same period last year, as net revenues inched up by 2.3 percent to $314 million from $307 million year-on-year.
The figures put the company at a $108 million net income in the first nine months of the year, reversing a $14 million net loss in the same period a year earlier. However, revenues dipped by nearly 1 percent to $881 million from $889 million year-on-year.
Following the results, Indivior PLC (NASDAQ:INDV) raised its full-year revenue growth guidance to a range of $1.18 billion to $1.22 billion from $1.03 billion to $1.08 billion previously.
Revenues from its Sublocade treatment alone are expected to rake in between $825 million and $845 million, higher than the $765 million to $785 million previously targeted.
Adjusted EBITDA outlook was also upgraded to $400 million to $420 million, versus $275 million to $300 million prior.
Hedge Fund Resource Center